Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

small-cap

One NASDAQ-Listed Pharmaceuticals Company Near Resistance Level: CPRX

Mar 05, 2026 | Team Kalkine
One NASDAQ-Listed Pharmaceuticals Company Near Resistance Level: CPRX
Image source: Shutterstock

  • CPRX:NASDAQ
  • Investment Type
    Mid - Cap
  • Risk Level
  • Action
  • Rec. Price (US$)

Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc. (NASDAQ: CPRX) is a commercial-stage biopharmaceutical company focused on the acquisition, development, and commercialization of therapies aimed at treating rare and difficult-to-manage medical conditions. The company’s current commercial portfolio includes three approved products: FIRDAPSE (amifampridine), FYCOMPA (perampanel), and AGAMREE (vamorolone).

As per Kalkine’s Diversified Opportunities Report published on ‘CPRX’ on Jul 24, 2025, Kalkine provided an ‘Buy’ stance on the stock at USD 21.57 based on fundamental analysis and the stock price has now moved up by ~ 14.46% since then.

Xxxxxx Xxxxxx Xxxxxx

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx Xxxxxx Xxxxxx & Xxxxxx

  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx
  • Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .

Xxxxxx

Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx Xxxxxx .   

Interested?

Enter your details below and our team will help you to decide if this product is best for you.

Please wait processing your request...
Disclaimer-

The advice given by Kalkine Canada Advisory Services Inc. and provided on this website is general information only and it does not take into account your investment objectives, financial situation and the particular needs of any particular person. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. The website www.kalkine.ca is published by Kalkine Canada Advisory Services Inc. The link to our Terms & Conditions has been provided please go through them. On the date of publishing this report (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.

Past performance is not a reliable indicator of future performance.

Blue-Chip
Coherent Corp: AI Datacenter Demand Drives Growth, While Segment Concentration and Execution Risks Remain
Jun 03, 2026 Team Kalkine
Small-Cap
How BMNU Works: The Mechanics of the REX 2X Long BMNR Daily Target ETF
Jun 03, 2026 Team Kalkine
Small-Cap
How RGTX Works: The Mechanics of the Defiance Daily Target 2X Long RGTI ETF
Jun 03, 2026 Team Kalkine
Blue-Chip
Is Cameco’s Nuclear Growth Story Fully Reflected in Its Valuation – CCO?
Jun 03, 2026 Team Kalkine
Blue-Chip
One NASDAQ - Listed Automobile Stock at Resistance Level – RIVN
Jun 03, 2026 Team Kalkine